EP Patent

EP3628319A1 — Methods of treating hepatic encephalopathy using rifaximin

Assigned to Salix Pharmaceuticals Inc · Expires 2020-04-01 · 6y expired

What this patent protects

The application concerns the reduction of the frequency of hospitalization visits for a subject having hepatic encephalopathy using rifaximin, administered orally at a defined daily dosage.

USPTO Abstract

The application concerns the reduction of the frequency of hospitalization visits for a subject having hepatic encephalopathy using rifaximin, administered orally at a defined daily dosage.

Drugs covered by this patent

Patent Metadata

Patent number
EP3628319A1
Jurisdiction
EP
Classification
—
Expires
2020-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Salix Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.